SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as news circulates about the departure of a key FDA official, which the community believes removes a significant hurdle and could accelerate the approval path for their Duchenne Muscular Dystrophy (DMD) therapy, Deramiocel; this development, combined with upcoming Phase 3 data presentations, is intensifying short squeeze and buyout speculation.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is surging as a key FDA official's departure and reports of a less invasive trial design for its Huntington's gene therapy ignite community hopes for accelerated approval, triggering a significant short squeeze after a week of regulatory setbacks.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is trending after completing an AI licensing partnership in Africa, which, combined with its low float and extremely high cost-to-borrow, is fueling intense short squeeze speculation among traders. The community is actively discussing strong buy-side pressure and the stock's resilience amidst a broader red market, with many holding for significant upside.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending amid widespread speculation and fervent debate among investors regarding its potential inclusion in the S&P 500. While many anticipate a significant price movement based on the decision, others express frustration over past dilutions and current market volatility, yet maintain confidence in the company's long-term growth and recent insider buying.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as escalating Middle East tensions and significant disruptions to the Strait of Hormuz drive oil prices to multi-year highs with historic weekly gains. Traders are fiercely debating whether this represents a sustainable "plumbing break" or an overextended "fear trade" ripe for a pullback, amidst discussions of potential US administration interventions to stabilize the market.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings (LITE) is trending amid its S&P 500 inclusion and a significant strategic investment from NVIDIA, solidifying its critical position in AI infrastructure expansion. The community is actively discussing whether its high valuation is justified by its role in supplying advanced optical components, particularly in light of industry perspectives on optical versus copper solutions for data center connectivity.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending with surging volume, fueled by intense short-covering and bullish community sentiment. Investors are optimistic about a significant re-rating, citing recent analyst upgrades, M&A buzz in the oncology sector, and anticipated data readouts for its promising TIL therapy platform.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the anticipated departure of a key FDA official fuels community speculation for a significantly softened regulatory landscape for gene therapies, with many expecting SRPT to follow recent rallies in comparable biotechs ahead of upcoming pivotal DM1 and FSHD data readouts.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending amid significant insider debt-to-equity conversions improving its balance sheet and aggressive CEO compensation goals, fueled by recent defense contracts, U.S. Army qualification, and plans for a massive new factory. Investors are weighing the company's critical role in aerospace and defense against persistent concerns about high short interest and potential dilution.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing extreme volatility, drawing polarized community sentiment between dip-buyers confident in long-term AI demand and short-sellers citing geopolitical concerns and the ETF's repeated failure to break key resistance. The leveraged semiconductor fund is seeing rapid swings, driven by mixed reactions to sector earnings and broader market uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Kyverna Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...

Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell

Wall Street Zen lowered Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of "Moderate Buy" by Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat.com reports...

Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised shares of Kyverna Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday...

Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen cut Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the company...

Kyverna Therapeutics Stock Up 41% in a Month: Here's Why

KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.

Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Buys 133,333 Shares

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) major shareholder Biopartners Opportuni Westlake purchased 133,333 shares of the firm's stock in a transaction dated Thursday, December...

Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Purchases 133,333 Shares

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) major shareholder Biopartners Opportuni Westlake acquired 133,333 shares of Kyverna Therapeutics stock in a transaction that occurred on...

Beth Seidenberg Purchases 133,333 Shares of Kyverna Therapeutics (NASDAQ:KYTX) Stock

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) Director Beth Seidenberg purchased 133,333 shares of the firm's stock in a transaction on Thursday, December 18th. The stock was acquired at...

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Current Price	$8.10
Prev Close	$8.39
Open	$8.35
Dividend Yield	0.00%
50-Day Moving Average	$8.43
Beta	1.91
Avg. Volume	579,825.13
PE Ratio	-2.25

52-Week High	$13.67
52-Week Low	$1.78
Market Capitalization	$479.32M
EPS (Annual)	-$3.33
Price to Book	2.42
Revenue Per Employee	$0.00

KYTX
Kyverna Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KYTX News

KYTXKyverna Therapeutics Inc.